Carole Bellis is a partner in the Silicon Valley office of Kilpatrick Townsend. Carole advises clients on the organization, financing, acquisition, and governance of privately held, emerging growth companies. She also represents investors in private company securities transactions and acquirers of privately held companies. Clients include companies in the medical device, biotech, healthcare, software, technology and consumer products industries.
Before attending law school, Carole was an executive in a government relations firm representing major corporations, foreign governments, professional and trade associations before the California state legislature. She began her legal career in Paris in 1997 and has been practicing in Silicon Valley since 1999.
Represented lead investors in $40 million Series C financing of Hyperfine Research, Inc.
Represented founders of Editas Medicine in $43 million Series A financing.
Represented MVRx in $6 million Series A financing.
Formation, Seed and Series A financings in stealth mode biotech company.
Represented Ctuit in merger with Compeat.
Represented acquirer in asset purchase of LifeHealth.
Insights View All
University of San Francisco School of Law, J.D.
Florida State University, B.S., Business Administration
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.